-- 周五下午晚些时候，医疗保健类股走低，纽约证券交易所医疗保健指数下跌1.1%，道富医疗保健精选行业SPDR ETF (XLV)下跌1.4%。 iShares生物技术ETF (IBB)下跌1%。 行业新闻方面，美国食品药品监督管理局(FDA)表示，将启动监管行动，支持开发用于治疗精神疾病的迷幻药疗法。FDA表示，此举是基于唐纳德·特朗普总统最近签署的行政命令，该命令指示卫生与公众服务部加快为严重精神疾病患者提供治疗。 公司新闻方面，HCA医疗保健公司(HCA)第一季度业绩超出市场预期，但这家医院运营商表示，由于呼吸系统疾病活动减少，其入院人数并未出现往常的季节性增长。该公司股价下跌9%。 据报道，印度太阳制药工业公司(Sun Pharmaceutical Industries)计划以130亿美元收购Organon (OGN)，受此消息提振，Organon股价飙升32%。 Compass Pathways (CMPS) 股价上涨 4.8%，此前该公司周五宣布，美国食品药品监督管理局 (FDA) 已批准其新药申请的滚动审查请求，并将 COMP360 纳入 FDA 的国家优先券计划，用于治疗难治性抑郁症。 赛诺菲 (SNY) 完成了其欧元中期票据计划下 23 亿欧元（27 亿美元）的票据发行定价。其股价下跌 1.5%。
Related Articles
Research
Research Alert: CFRA Maintains Hold Rating On Shares Of United Rentals Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target price to $1,100 from $950 following a strong first quarter, valuing shares at 20.5x our 2027 EPS outlook of $54.28 (in line with previous estimate; 2026 EPS also in line). We believe a higher multiple is justified given URI's firming market leadership within an expanding rental equipment industry. A robust Q1 beat enabled URI to raise its full-year revenue guidance to $16.9B-$17.4B and adjusted EBITDA to $7.625B-$7.875B, citing momentum heading into a busy season. With leverage well below historical levels, we believe accretive M&A deals could serve as a potential catalyst for additional guidance increases. Margin compression has been a sticky issue for URI, but Q1 indicated that pricing may have turned around and that headwinds are starting to ease as quarterly results begin to lap when tariff-related inflation began to pick-up. We remain cautious on margins, though are encouraged by signs of stabilization. New project activity is likely supporting pricing trends, in our view.
$URI
Equities
Petro Rabigh Emerges From Loss in Q1; Revenue Grows
Rabigh Refining and Petrochemical (SASE:2380), d/b/a Petro Rabigh, said Sunday it swung back to profit in the first quarter of 2026, while revenue increased year over year.Net profit attributable to shareholders of the issuer for the three months ended March 31 was 1.47 billion Saudi riyals, compared with the attributable loss of 691 million riyals earlier. EPS moved to 0.88 riyal from a loss per share of 0.41 riyal.The Tadawul-listed oil refining and petrochemical company's revenue was 14.85 billion riyals, compared with 11.21 billion riyals a year ago.
$SASE:2380
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.
$HIG